Stem cell treatment for lung scarring in scleroderma
Treatments studied
Part of Immune system & allergy, Lungs & breathing clinical trials.
This trial tests a new treatment using stem cells from umbilical cords to help people with scleroderma-related lung disease. It aims to see if the treatment can slow down or improve lung scarring and breathing problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have scleroderma (a condition that causes hardening of the skin and can affect organs).
- A CT scan of your chest shows lung scarring (fibrosis) in at least 10% of your lungs.
- Your lung function tests show moderate damage, and your lung disease has been getting worse despite current treatment.
- You are able to do a 6-minute walk test and understand how to do breathing tests.
- You do not have other serious lung diseases, recent infections, or severe heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental treatment using tiny particles from human stem cells, given through a nebulizer (breathing mist). It aims to see if this treatment is safe and can help improve lung function in people with interstitial lung disease (lung scarring).
This trial tests giving stem cells from a healthy donor to people with severe scleroderma that affects their lungs or heart. The goal is to see if these donor stem cells can calm the immune system and ease symptoms when standard treatments have stop working.
This study tests whether a combination of two drugs, nintedanib and tocilizumab, can help people with systemic sclerosis (a condition that causes skin and organ hardening) who also have lung scarring (interstitial lung disease). The goal is to find a treatment that can slow down the disease.
This trial tests new treatments for people with scleroderma-related lung disease. You may be eligible if you have systemic sclerosis with lung scarring, your symptoms started within the last 7 years, and you have not had certain prior treatments or transplants.
This trial tests whether combining two drugs, rituximab and mycophenolate mofetil, is safe and works better than standard care for lung scarring caused by scleroderma. It may be an option if your lung disease is severe or getting worse.
This trial tests whether stem cells from umbilical cord blood can help treat systemic sclerosis (scleroderma). The goal is to see if this treatment can improve skin thickening and overall symptoms for people who haven't had success with standard therapies.
Hear when a new CTD-ILD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.